Repetitive	repetitive	O	O
transcranial	transcranial	O	O
magnetic	magnetic	O	O
stimulation	stimulation	O	O
for	for	O	O
levodopa-induced	levodopa-induced	O	O
dyskinesias	dyskinesias	O	S_disease
in	in	O	O
Parkinson	parkinson	O	B_disease
's	's	O	I_disease
disease	disease	O	I_disease
.	.	O	O

In	in	O	O
a	a	O	O
placebo-controlled	placebo-controlled	O	O
,	,	O	O
single-blinded	single-blinded	O	O
,	,	O	O
crossover	crossover	O	O
study	study	O	O
,	,	O	O
we	we	O	O
assessed	assessed	O	O
the	the	O	O
effect	effect	O	O
of	of	O	O
"	"	O	O
real	real	O	O
"	"	O	O
repetitive	repetitive	O	O
transcranial	transcranial	O	O
magnetic	magnetic	O	O
stimulation	stimulation	O	O
(	(	O	O
rTMS	rtms	O	O
)	)	O	O
versus	versus	O	O
"	"	O	O
sham	sham	O	O
"	"	O	O
rTMS	rtms	O	O
(	(	O	O
placebo	placebo	O	O
)	)	O	O
on	on	O	O
peak	peak	O	O
dose	dose	O	O
dyskinesias	dyskinesias	O	S_disease
in	in	O	O
patients	patients	O	O
with	with	O	O
Parkinson	parkinson	O	B_disease
's	's	O	I_disease
disease	disease	O	I_disease
(	(	O	O
PD	pd	O	S_disease
)	)	O	O
.	.	O	O

Ten	ten	O	O
patients	patients	O	O
with	with	O	O
PD	pd	O	S_disease
and	and	O	O
prominent	prominent	O	O
dyskinesias	dyskinesias	O	S_disease
had	had	O	O
rTMS	rtms	O	O
(	(	O	O
1,800	1,800	O	O
pulses	pulses	O	O
;	;	O	O
1	1	O	O
Hz	hz	O	O
rate	rate	O	O
)	)	O	O
delivered	delivered	O	O
over	over	O	O
the	the	O	O
motor	motor	O	O
cortex	cortex	O	O
for	for	O	O
4	4	O	O
consecutive	consecutive	O	O
days	days	O	O
twice	twice	O	O
,	,	O	O
once	once	O	O
real	real	O	O
stimuli	stimuli	O	O
and	and	O	O
once	once	O	O
sham	sham	O	O
stimulation	stimulation	O	O
were	were	O	O
used	used	O	O
;	;	O	O
evaluations	evaluations	O	O
were	were	O	O
done	done	O	O
at	at	O	O
the	the	O	O
baseline	baseline	O	O
and	and	O	O
1	1	O	O
day	day	O	O
after	after	O	O
the	the	O	O
end	end	O	O
of	of	O	O
each	each	O	O
of	of	O	O
the	the	O	O
treatment	treatment	O	O
series	series	O	O
.	.	O	O

Direct	direct	O	O
comparison	comparison	O	O
between	between	O	O
sham	sham	O	O
and	and	O	O
real	real	O	O
rTMS	rtms	O	O
effects	effects	O	O
showed	showed	O	O
no	no	O	O
significant	significant	O	O
difference	difference	O	O
in	in	O	O
clinician-assessed	clinician-assessed	O	O
dyskinesia	dyskinesia	O	S_disease
severity	severity	O	O
.	.	O	O

However	however	O	O
,	,	O	O
comparison	comparison	O	O
with	with	O	O
the	the	O	O
baseline	baseline	O	O
showed	showed	O	O
small	small	O	O
but	but	O	O
significant	significant	O	O
reduction	reduction	O	O
in	in	O	O
dyskinesia	dyskinesia	O	S_disease
severity	severity	O	O
following	following	O	O
real	real	O	O
rTMS	rtms	O	O
but	but	O	O
not	not	O	O
placebo	placebo	O	O
.	.	O	O

The	the	O	O
major	major	O	O
effect	effect	O	O
was	was	O	O
on	on	O	O
dystonia	dystonia	O	S_disease
subscore	subscore	O	O
.	.	O	O

Similarly	similarly	O	O
,	,	O	O
in	in	O	O
patient	patient	O	O
diaries	diaries	O	O
,	,	O	O
although	although	O	O
both	both	O	O
treatments	treatments	O	O
caused	caused	O	O
reduction	reduction	O	O
in	in	O	O
subjective	subjective	O	O
dyskinesia	dyskinesia	O	S_disease
scores	scores	O	O
during	during	O	O
the	the	O	O
days	days	O	O
of	of	O	O
intervention	intervention	O	O
,	,	O	O
the	the	O	O
effect	effect	O	O
was	was	O	O
sustained	sustained	O	O
for	for	O	O
3	3	O	O
days	days	O	O
after	after	O	O
the	the	O	O
intervention	intervention	O	O
for	for	O	O
the	the	O	O
real	real	O	O
rTMS	rtms	O	O
only	only	O	O
.	.	O	O

Following	following	O	O
rTMS	rtms	O	O
,	,	O	O
no	no	O	O
side	side	O	O
effects	effects	O	O
and	and	O	O
no	no	O	O
adverse	adverse	O	O
effects	effects	O	O
on	on	O	O
motor	motor	O	O
function	function	O	O
and	and	O	O
PD	pd	O	S_disease
symptoms	symptoms	O	O
were	were	O	O
noted	noted	O	O
.	.	O	O

The	the	O	O
results	results	O	O
suggest	suggest	O	O
the	the	O	O
existence	existence	O	O
of	of	O	O
residual	residual	O	O
beneficial	beneficial	O	O
clinical	clinical	O	O
aftereffects	aftereffects	O	O
of	of	O	O
consecutive	consecutive	O	O
daily	daily	O	O
applications	applications	O	O
of	of	O	O
low-frequency	low-frequency	O	O
rTMS	rtms	O	O
on	on	O	O
dyskinesias	dyskinesias	O	S_disease
in	in	O	O
PD	pd	O	S_disease
.	.	O	O

The	the	O	O
effects	effects	O	O
may	may	O	O
be	be	O	O
further	further	O	O
exploited	exploited	O	O
for	for	O	O
potential	potential	O	O
therapeutic	therapeutic	B_chemical	O
uses	uses	I_chemical	O
.	.	O	O

